A Phase II Study of Maintenance Biotherapy With Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor in Patients With Metastatic Melanoma With a Partial Response or Stable Disease After Systemic Therapy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2; Sargramostim
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 Dec 2012 Biomarkers information updated
- 16 Jan 2008 New trial record.
- 01 Mar 2005 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.